Pharma BD Deal Intelligence
Teva Pharmaceutical Industries Ltd. / Ratiopharm
2010 · Acquisition/Merger · $5.0B · Complete
Announcement Sentiment
75
Strongly positive
Outcome Score
74
Largely worked — most objectives met.
Teva acquired Ratiopharm for $5B, a German generic pharmaceutical company.
Did it work? Outcome assessment
Teva / Ratiopharm: Achieved Stated Rationale (Score: 67/100)
Strategic verdict
Achieved Stated Rationale
Assessment window: 5yr post-close.
Key facts
- Announced Mar 18, 2010
- Closed Aug 10, 2010
- Deal value $5.0B
- Deal type Acquisition/Merger
- Therapeutic area Neurology
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals